top of page
3837507 probi.png
microbiome drug database logo 2.png

Sandwalk, in collaboration with the Microbiome Times, has developed the most comprehensive publicly available global database of microbiome biotechs developing pharmaceuticals, consisting of 309 biotechnology companies and 1,250+ active research programs


It is a tool designed for business development, M&A target scouting and technology analysis for companies and individuals interested in microbiome drug development.


Given the dynamic nature of the growing microbiome industry, it is updated on a regular basis, to depict as accurately as possible, the current landscape of microbiome drug biotechs.


Only entities developing pharmaceuticals and/or diagnostics for human use from or through the microbiome are included.

Download the Brochure here:

Microbiome Drug Database Brochure

Therapeutic Area

Application Cluster.png

Browse by the Therapeutic Approach employed by each research programme, including:

  • Infectious diseases: Clostridioides difficile, highly-selective antimicrobials against specific pathogens, urinary tract infections, implant-associated infections.

  • Gut-Brain axis: Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression.

  • Oncology: stand-alone or adjuvant treatment for cancer, as well as supportive care for side effects of oncology treatment.

  • Immune-mediated diseases: Inflammatory diseases, autoimmune diseases, multiple sclerosis, allergies, psoriasis.

  • Metabolic diseases: obesity, diabetes, cardiovascular disease, inborn errors of metabolism.

  • Gastrointestinal diseases: Irritable Bowel Disease, reflux and Gastroesophageal reflux disease, celiac disease.

  • Dermatology: atopic dermatitis, acne.

  • Other: women’s health, Sexually Transmitted Diseases, rare diseases, fertility.

Microbiome Approach

Search by each research programme’s Therapeutic Application, including:

  • FMT(Fecal Transplant): this approach involves the transfer of more or less processed fecal microbiome material from a healthy donor to a diseased individual.

  • Defined Consortia: based on treating the patient with a consortium of several microbial species. Whereas some of these products have emerged from further processing and refinement of FMT, some others have been designed rationally attending at ecological properties, metabolic capacities or other features.

  • Single species (strain): a single type of microorganism is administered to elicit the beneficial effect.

  • Phages and viruses: using bacteriophages to kill bacteria and/or modulate the composition or activity of the microbiome, or mining for human viruses to find novel tools for human gene therapy (although the gene therapies themselves would be excluded from the scope of LBPs). Some viruses are native and others are engineered.

  • GMOs( Genetically-Modified Organisms): engineering microbes to turn them into long-term drug delivery systems, or to expand or potentiate their metabolic activity.

  • Molecules from the microbiome (also called postbiotics): Molecules (small molecules but also some biologics) originally mined from the microbiome and employed as therapeutic actives, with or without prior modification.

  • Molecules for the microbiome: external chemicals (mostly small molecules, but also some biologics such as monoclonal antibodies) employed to therapeutically alter microbial activity and/or composition in the microbiome.

  • Diagnostics, companion diagnostics and disease-monitoring technologies: microbial signatures and biomarkers have been linked with the risk of developing a disease or with its prognosis.

Microbiome Approach.png

Research Stage

Phases of Clinical Trials.png

Filter by the Stage in which is research program currently is. A useful tool to search preclinical vs clinical-stage companies.

  • Pharmaceuticals were assigned one of the following categories: Discovery, Preclinical, Phase 1, Phase 2, Phase 3 and Market. In mixed phases (e.g. Phase 1/2 trials) the program was assigned the most advanced phase (Phase 2 in this example).

  • When “Early stage development” or similar classification was provided by the developer, the stage “Discovery” was assigned

  • Diagnostics were assigned one of the following categories: Discovery, Validation and Market.

Research phase is assigned according to the public information from the developer’s website or other sources:


Find companies by Geography. Whereas over the majority of microbiome biotechs are based in the USA, Canada or Europe, a growing number of them are being founded in other geographies like China, South Korea and Israel.

The world was divided into 3 areas:

  • EU: Europe, including the UK

  • US & CA: United States of America and Canada

  • ROW: Rest of the World

Georgraphy of Biotechs.png
Have any questions? Contact us

We're here to support you. Contact us by email or LinkedIn. 

bottom of page